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Although prostate-specific antigen (PSA) screening has improved the detection of prostate cancer, allowing for
stage migration to less advanced disease, the precise mortality benefit of early detection is unclear. This is in part
due to a discrepancy between the two large randomized controlled trials comparing PSA screening to usual care.
The European Randomized Study of Screening for Prostate Cancer (ERSPC) found a survival benefit to screening,
while the United States Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial did not. Furthermore,
the benefit of immediate surgical intervention for screen-detected prostate cancer is unclear, as the results
superficially differ between the two large randomized controlled trials comparing prostatectomy to observation.
The Prostate Cancer Intervention Versus Observation Trial (PIVOT) found no survival benefit for prostatectomy in
PSA screened U.S. men, while the Scandinavian Prostate Cancer Group Study Number Four (SPCG-4) found a
survival benefit for prostatectomy in clinically diagnosed prostate cancer. As a result of the controversy surrounding
PSA screening and subsequent prostate cancer treatment, guidelines vary widely by organization.
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In 1991 Catalona and colleagues first reported the use of
prostate-specific antigen (PSA) for prostate cancer (PCa)
screening [1]. The adoption of PSA screening in the
United States dramatically increased the detection of
PCa, particularly organ-confined disease [2-4]. Between
1986 and 1993, the incidence of PCa increased from 86
to 179 cases per 100,000 white men and 124 to 250
cases per 100,000 black men. However, the rate of dis-
tant disease at the time of diagnosis fell from 14.9 to 6.6
cases per 100,000 men during the same time period [5].
Some feared that PSA screening would contribute to
overdiagnosis and subsequent overtreatment of PCa, with
potential net unfavorable effects on patient mortality and
quality of life [6]. This was in part due to observations that
men with localized, low-grade PCa had low disease-
specific ten-year mortality, and those with life expectancy
less than ten years experienced no change in survival with
conservative management [7-9]. In order to accurately
assess the benefit of PSA screening, the United States* Correspondence: andrioleg@wudosis.wustl.edu
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Screening Trial and the European Randomized Study of
Screening for Prostate Cancer (ERSPC) were conceived
[10,11].
The discordant results of these studies have led to fur-
ther controversy regarding PSA screening, evidenced by
the differences among various PCa screening guidelines
[12]. We briefly present the findings and limitations of the
studies that have contributed to this controversy, as well as
summarize the various PSA screening recommendations.
No benefit with PSA screening in the United
States
From 1993 to 2001, the PLCO screening trial randomly
assigned 76,693 men aged 55 to 74 years to annual PSA
screening or usual care. Annual PSA testing was offered
for six years, and screening also included digital rectal
examination (DRE). Exclusion criteria included history
of PCa and more than one PSA test in the three years
prior to randomization [13].
After 13-year follow-up, the incidence of PCa was sig-
nificantly higher in the screening arm (relative increase
of 12%). However, the rate of PCa death was very low inntral. This is an Open Access article distributed under the terms of the Creative
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and the difference was not statistically significant [14].
Explanations for the lack of mortality reduction seen
with PSA screening in the PLCO trial include: 1) con-
tamination of the control group, as 40 to 52% of patients
in the usual care arm received PSA screening; 2) elimin-
ation of PCa cases prior to randomization, as 44% of pa-
tients had undergone one or more PSA tests prior to
randomization; 3) no PSA threshold for biopsy (PSA re-
sults were reported to primary care physicians and a
“community standard” for biopsy was applied at various
centers), while the ERSPC authors used PSA cutoffs of
2.5 and 3.0 ng/mL, which was likely more sensitive.
Survival benefit with PSA screening in Europe
From 1994 to 2000, the ERSPC trial randomly assigned
182,160 men aged 50 to 74 years to PSA screening at
an average of once every four years or no screening.
PSA testing was offered every four years at six out of
seven centers and every two years in Sweden. A PSA
value ≥3.0 ng/mL was an indication for biopsy at most
centers. Patients with a history of PCa diagnosis were
excluded [15].
At 11-year follow-up, the incidence of PCa was signifi-
cantly higher in the screening arm (rate ratio 1.63), and
the rate of PCa death was significantly reduced in the
screening arm (rate ratio 0.79), with the number needed
to screen to prevent one PCa death (NNS) equal to
1,055 men [16]. At 13-year follow-up, PSA screening
demonstrated further mortality reduction, with NNS de-
clining to 781 men [17].
The limitation of the ERSPC is the heterogeneity of data
due to multiple centers using different screening intervals
and PSA thresholds for biopsy. The greatest benefit to
PSA screening was realized in the Swedish arm of ERSPC,
the Goteborg trial, where 20,000 men were randomized to
invitation to biannual PSA screening versus no invitation.
At 14-year follow-up, the screening group had significant
reductions in PCa death (rate ratio 0.56, NNS 293) [18].
However, other centers showed no significant benefit from
PSA screening, including Finland, which had the largest
enrollment of the ERSPC sites and very high overall PCa
incidence and mortality [19].
Effective screening requires an effective
treatment: prostatectomy versus observation
The Prostate Cancer Intervention Versus Observation
Trial (PIVOT) randomly assigned 731 men with localized
PCa, diagnosed with PSA screening, to prostatectomy or
observation with delayed androgen deprivation therapy
(ADT). At 12-year follow-up, the prostatectomy group had
no significant overall or PCa-specific survival benefit [20].
The Scandinavian Prostate Cancer Group Study Number
Four (SPCG-4) randomly assigned 695 men with localizedPCa, diagnosed by DRE or on transurethral resection spe-
cimen, to prostatectomy or watchful waiting with de-
layed ADT. At 15-year follow-up, the prostatectomy
group had both a significant overall and PCa-specific
survival benefit compared to observation, with the num-
ber needed to treat to prevent one PCa death (NNT)
equal to 15 men. The benefit was confined to men youn-
ger than 65 years of age on subset analysis, with NNT
equal to 7 men in this group [21].
The mortality difference between PIVOT and SPCG-4
was substantial; the relative reduction in overall mortal-
ity was 12% versus 25% and the absolute reduction in
overall mortality was 2.6% versus 6.6%, respectively. This
was likely a result of PIVOT enrollment of an older
population (only 10% of patients were younger than
60 years of age) with less advanced PCa (50% nonpalp-
able versus 12% in SPCG-4). As a result, the overall rate
of PCa death in PIVOT was much lower, 7.1% versus
19.6%.Summary of current PSA screening guidelines
PCa screening recommendations vary by organization
and are summarized in Table 1. Baseline PSA testing is
recommended by some groups, based on the Malmo
Preventive Project, where a strong association was found
between PSA at age 44 to 50 years and future diagnosis
of advanced PCa [22].Conclusions
The cause of discrepancy between the major PSA scree-
ning trials may be a result of differences in study design,
screening protocol, and biopsy threshold: PLCO com-
pared annual to opportunistic screening and relied on
the community standard for indication to biopsy, while
ERSPC compared biennial to quadrennial screening to
no screening and defined a PSA cutoff for biopsy. As for
the major intervention trials, PIVOT found that prosta-
tectomy for PSA-diagnosed low-risk PCa may provide
limited benefit, while SPCG-4 found that the same treat-
ment is beneficial for younger patients with clinically
diagnosed PCa. The forthcoming results (expected in
2016) of the Prostate Testing for Cancer and Treatment
(ProtecT) trial should provide further insight regarding
survival and quality of life for patients with localized
PCa diagnosed by PSA screening randomized to active
monitoring, prostatectomy, or radiotherapy [30].
Although the current guidelines regarding PSA screen-
ing differ by organization, overall they reflect the im-
portant findings of the above studies: 1) PSA screening
should be offered only to men with reasonable life
expectancy, 2) screening should be performed on a
biennial or greater basis to minimize overdiagnosis, 3)
additional data may be used to provide risk adjustments





Invitation to screening* (age) High risk groups** (age) Screening interval PSA threshold for biopsy (ng/mL)
American Cancer
Society [23]
2010 None Beginning at 50 years while life
expectancy ≥ 10 years
Beginning at 40 years while
life expectancy≥ 10 years
- Annually if PSA≥ 2.5 ng/mL - 2.5 ng/mL in select patients
- Every 2 years if PSA < 2.5 ng/mL - 4.0 ng/mL in most patients
U.S. Preventive Services
Task Force [24]
2012 None None None None None
American Urological
Association [25]
2013 None 55 - 69 years 40 - 69 years Every 2 years None specified
European Association of
Urology [26]
2013 40 - 45 years Any age while life expectancy≥
10 years
Any age while life
expectancy≥ 10 years
- Every 2 to 4 years if baseline
PSA > 1 ng/mL
None specified
- Every 8 years if baseline PSA≤ 1 ng/mL
American College of
Physicians [27]
2013 None 50 - 69 years 40 - 69 years Annually if PSA≥ 2.5 ng/mL None specified
National Comprehensive
Cancer Network [28]
2014 45 - 49 years 50 - 70 Consider change in
biopsy threshold
For 40 - 49 years: - 3.0 ng/mL
years - Every 1 - 2 years if PSA > 1 ng/mL - <3.0 ng/mL with excess risk based
on multiple factors (family history,
race, PSA kinetics)70 - 75 years if life expectancy≥
10 years
- Repeat at age 50 if PSA≤ 1 ng/mL
For 50 - 70 years:
- Every 1 - 2 years
Melbourne Consensus
Statement [29]
2014 40 - 49 years 50 - 69 years Use to better risk
stratify men
None specified None specified
70+ years while life expectancy≥
10 years
*For men who are well-informed on the risks and benefits of PSA screening.
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importantly 4) the decision to undergo PSA screening
should be made by both the provider and the well-
informed patient after a complete discussion of the po-
tentially limited benefit and associated harms of early
PCa detection and treatment.
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